Online inquiry

IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12706MR)

This product GTTS-WQ12706MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets DLL4 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_019074.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567
UniProt ID Q9NR61
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12706MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12306MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ2915MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ9709MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ7002MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ4648MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ12509MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ3040MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ7286MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW